Search
Now showing items 1-1 of 1
Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma
(Blood Cancer Journal, 2019-03-29)
This phase I dose-escalation/expansion study evaluated isatuximab (anti-CD38 monoclonal antibody) monotherapy in patients with relapsed/refractory multiple myeloma (RRMM). Patients progressing on or after standard therapy ...